The purpose of this study is to evaluate the diabetes related treatment satisfaction for patients with type 2 diabetes mellitus

This is a cross-sectional, observational patient survey study. Study subjects will be adult commercial members of the large US health plan affiliated with Optum with evidence of T2D initiating dapagliflozin or a sulfonylurea medication within the 3 months prior to survey mailing.

Inclusion Criteria:

• At least one pharmacy claim for dapagliflozin or dapagliflozin/metformin ER in the most recent month of pharmacy data and no pharmacy claims for an SGLT2 medication during the 6 months prior to sample identification.
• Evidence of T2D diagnosis.
• Age ≥18 as of the drug index date.
• 6 months of continuous enrollment in a commercial health plan with both pharmacy and medical benefits during the identification period through the patient interview sample identification date.
• Self-reported T2D diagnosis during the patient interview.

Exclusion Criteria:

• Patients with evidence of type 1 diabetes mellitus and unknown type
• Patients who are pregnant

Type 2 Diabetes patients with administrative claims data from Optum Research Database (US Commercial Claims Data)